Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.74 |
| ▸ | PDE4A | P27815 | 2/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.74 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844053 | 0.96 | PDE4D (0.72) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6844077 | 0.93 | MET (0.77) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6842253 | 0.92 | MET (0.75) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6844136 | 0.91 | MET (0.74) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6841728 | 0.89 | MET (0.75) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL12513343 | 0.88 | MET (0.72) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6842260 | 0.87 | PDE4B (0.73) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6841791 | 0.87 | PDE4D (0.60) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6657249 | 0.87 | PDE4D (0.62) | METPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL6837229 | 0.87 | PDE4D (0.59) | METPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | MET 4676/4885PDE4D 12/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.